The Biospecimen Core (Core A) provides part of the infrastructure support for Projects 1-3. This Core will provide a well-organized and standardized system of specimen collection, storage, distribution and related clinical/research information dissemination that is based on over two decades of experience. There will be consistency and quality assurance in the pathological analysis of tissue specimens. The Biospecimen Core is also involved in the maintenance of a large series of prostate cancer xenograft lines developed by Core investigators. These xenografts are used for a number of studies by the POI investigators and each study is overseen by Core personnel. Overall, the operations of this Core group into 5 components: 1. Specimen acquisition, processing, quality control, storage and accessioning into databases; 2. A development program to continually improve the quality and efficiency with which we obtain tissue samples and derivative products; 3. A prostate cancer xenograft maintenance, development and study program. 4. Laboratory services, including interpretation of tissues and tissue localization studies by a urologic pathologist, immunohistochemistry (IHC), quantitative RT-PCR, and immunoassays, i.e. PSA, and tissue culture. The Core will also perform pre-clinical studies using our xenograft resources;and 5. An administrative program to obtain samples from minority patients, prioritize the distribution of specimens, conduct a quality control program, and to ensure patient confidentiality and compliance with IRB requirements. Furthermore, the Core provides biostatistical support to all of the project investigators. The performance of each of the research projects detailed in this program project mandates that investigators have ready access to well documented clinical specimens and relevant biological models. The investigators directing the Biospecimen Core also make it a policy to provide excess prostate cancer specimen resources to non-PPG investigators on a world-wide basis. Overall, the Biospecimen Core is a critical component of this P01 program project.

Public Health Relevance

The Biospecimen Core is not hypothesis driven yet it is an essential component of this POI that enables the investigative teams to conduct hypothesis driven projects. Without adequate specimens and tumor models, both in quantity and quality, the science conducted by these investigators can not be robust. This Core assures that they are and futhermore provides outstanding statistical support for analyses of data.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-O)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Washington
United States
Zip Code
Damodarasamy, Mamatha; Vernon, Robert B; Chan, Christina K et al. (2015) Hyaluronan in aged collagen matrix increases prostate epithelial cell proliferation. In Vitro Cell Dev Biol Anim 51:50-8
Long, Thomas J; Sprenger, Cynthia C; Plymate, Stephen R et al. (2014) Prostate cancer xenografts engineered from 3D precision-porous poly(2-hydroxyethyl methacrylate) hydrogels as models for tumorigenesis and dormancy escape. Biomaterials 35:8164-74
Chéry, Lisly; Lam, Hung-Ming; Coleman, Ilsa et al. (2014) Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways. Oncotarget 5:9939-51
Lucas, Jared M; Heinlein, Cynthia; Kim, Tom et al. (2014) The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov 4:1310-25
Gordon, Ryan R; Wu, Mengchu; Huang, Chung-Ying et al. (2014) Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes. PLoS One 9:e104271
Tang, Xi; Mahajan, Sumit S; Nguyen, Liem T et al. (2014) Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis. Oncotarget 5:1352-62
Vela, I; Morrissey, C; Zhang, X et al. (2014) PITX2 and non-canonical Wnt pathway interaction in metastatic prostate cancer. Clin Exp Metastasis 31:199-211
Chevillet, John R; Kang, Qing; Ruf, Ingrid K et al. (2014) Quantitative and stoichiometric analysis of the microRNA content of exosomes. Proc Natl Acad Sci U S A 111:14888-93
Thadani-Mulero, Maria; Portella, Luigi; Sun, Shihua et al. (2014) Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res 74:2270-82
Yu, X; Cates, J M; Morrissey, C et al. (2014) SOX2 expression in the developing, adult, as well as, diseased prostate. Prostate Cancer Prostatic Dis 17:301-9

Showing the most recent 10 out of 118 publications